Akero Therapeutics Acquisition Finalized, Shares Delisted from Nasdaq

The publicly traded chapter for Akero Therapeutics has officially closed. The company’s shares, previously listed under the ticker symbol “AKRO” on the Nasdaq, have been removed from trading boards following the completion of its acquisition by Danish pharmaceutical leader Novo Nordisk. The deal, which received shareholder approval, was formally concluded on December 9.

Trading in Akero Therapeutics stock was halted prior to market open on December 10. The biopharma firm now operates as a wholly-owned subsidiary within the Novo Nordisk corporate structure.

For investors who held their shares through the acquisition, the transaction triggers an immediate cash payout. Novo Nordisk is paying $54.00 per share, a figure that values the Read more...